Sequoia Financial Advisors LLC Purchases 400 Shares of United Therapeutics Corporation $UTHR

Sequoia Financial Advisors LLC boosted its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 60.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,067 shares of the biotechnology company’s stock after purchasing an additional 400 shares during the period. Sequoia Financial Advisors LLC’s holdings in United Therapeutics were worth $307,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Chung Wu Investment Group LLC bought a new position in United Therapeutics during the 2nd quarter valued at about $29,000. SVB Wealth LLC bought a new position in United Therapeutics during the 1st quarter valued at about $32,000. Geneos Wealth Management Inc. lifted its holdings in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the last quarter. Brooklyn Investment Group lifted its holdings in United Therapeutics by 103.2% during the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 98 shares during the last quarter. Finally, WPG Advisers LLC bought a new position in shares of United Therapeutics in the first quarter worth about $60,000. 94.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on UTHR. UBS Group boosted their target price on shares of United Therapeutics from $560.00 to $580.00 and gave the stock a “buy” rating in a research note on Monday, September 29th. Bank of America boosted their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 2nd. Royal Bank Of Canada began coverage on shares of United Therapeutics in a research note on Friday, September 26th. They issued an “outperform” rating and a $569.00 target price for the company. HC Wainwright boosted their target price on shares of United Therapeutics from $400.00 to $500.00 and gave the stock a “buy” rating in a research note on Friday, September 5th. Finally, JPMorgan Chase & Co. dropped their target price on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a research note on Tuesday, July 8th. Nine investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $461.62.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $421.64 on Thursday. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $459.48. The company has a 50 day moving average of $393.00 and a 200-day moving average of $330.45. The stock has a market cap of $19.02 billion, a price-to-earnings ratio of 16.46, a P/E/G ratio of 4.60 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). The firm had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm’s revenue for the quarter was up 11.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.85 EPS. Equities research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Paul A. Mahon sold 11,000 shares of the business’s stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $308.75, for a total transaction of $3,396,250.00. Following the completion of the transaction, the executive vice president owned 36,781 shares in the company, valued at approximately $11,356,133.75. The trade was a 23.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total transaction of $9,396,900.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 322,935 shares of company stock valued at $133,361,282. Corporate insiders own 10.30% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.